Skip to content
Mesothelioma.net
phone iconCall1-800-692-8608 chat icon Chat 24/7 Live Chat
Menu
  • Malignant Mesothelioma
    • About Mesothelioma
      • How to Survive Mesothelioma
      • 100 Questions & Answers about Mesothelioma (Free Book)
      • Symptoms
      • Diagnosis
      • Prognosis
      • Life Expectancy
    • Types
      • Pleural
      • Peritoneal
      • Epithelioid
      • Sarcomatoid
      • Biphasic
    • Stages
      • Stage 1
      • Stage 2
      • Stage 3
      • Stage 4
    • Additional Information
      • Causes
      • Asbestos and Its Dangers
      • Facts
      • Support
      • Financial Compensation
      • FREE Mesothelioma Packet
  • Treatment
    • Treatment Options
      • Surgery
      • Chemotherapy
      • Radiation Therapy
      • Multimodal Therapy
      • Medications
      • Palliative Treatment
    • Find Top Doctors
      • Doctors
      • Treatment Centers
      • Treatment & Doctors Near You
      • New Treatments
      • Care Providers
      • Clinical Trials
      • Costs
  • Asbestos Trusts
  • Compensation
  • Veteran Assistance
    • Mesothelioma and Veterans
      • VA Claims for Mesothelioma
      • Vietnam Veterans
    • Military Branches and Asbestos
      • Navy Veterans
      • Navy Ships
      • Marine Corps Veterans
      • Army Veterans
      • Air Force Veterans
      • U.S. Coast Guard
  • Surviving Mesothelioma
  • About Us / Contact
  • Home
  • ›
  • Malignant Mesothelioma
  • ›
  • Treatment
  • ›
  • Medications
  • ›
  • Keytruda (Pembrolizumab)
Page Updated: June 27, 2022

Keytruda (pembrolizumab)

Kyle J. Becker Page Medically Reviewed and Edited by Kyle J. Becker, PharmD, MBA, BCOP

FREE Mesothelioma Packet

Fact Checked

This page has been fact checked by a Doctor of Pharmacy who specializes in Oncology. Sources of information are listed at the bottom of the article.

FREE Mesothelioma Packet

We make every attempt to keep our information accurate and up-to-date.

Please Contact Us with any questions or comments.

Keytruda (pembrolizumab) is approved to treat cancers with a specific biomarker, the first drug approved by the U.S. Food and Drug Administration (FDA) based on cancer genetics.[1][2] For people affected by asbestos exposure, Keytruda is exciting because early studies suggest it may be a useful chemotherapy drug for mesothelioma. While more research is necessary, results are promising.

FREE Mesothelioma Packet

Pembrolizumab and Immunotherapy

Keytruda is an immunotherapy drug designed to help the immune system identify and attack cancer cells.[2] The immune system recognizes and attacks foreign invaders in the body. Immune system cells recognize some pathogens because of receptors called antigens on their surfaces. 

Healthy cells in the body have receptors on their surfaces that signal immune cells to leave them alone. Some cancer cells express these same receptors, called PD-1 proteins. This causes immune cells to mistake cancer cells for healthy cells and leave them alone to grow and thrive.[2]

Pembrolizumab acts on these cancer cell receptors, helping the immune system recognize them as foreign and attack them. This strategy is sometimes referred to as the immune checkpoint blockade.

Indications and Side Effects

The FDA approved Keytruda for specific types of cancers, cancers in certain stages or with certain characteristics, and cancer patients with certain biomarkers. For example, it is approved for melanoma, but only melanoma that has spread and cannot be treated surgically.

For other cancers, like non-small cell lung cancer, Keytruda is approved only in cases where the patient’s cancer worsened after treatment with standard chemotherapy drugs.

The side effects associated with pembrolizumab can be serious. Contact your doctor immediately if you have an unusual cough or diarrhea.

The most common side effects include:[1]

  • Fatigue
  • Rash
  • Diarrhea
  • Constipation
  • Nausea
  • Decreased appetite
  • Shortness of breath
  • Coughing
  • Itching

More serious side effects are less common but may include:[1]

  • Bruising
  • Anemia
  • Numbness
  • Dizziness
  • Hot flashes
  • Flu-like symptoms
  • Hair loss
  • Edema
  • Irregular heartbeat
  • Pain
  • Kidney failure
  • Infections
  • Insomnia
  • Diabetes
  • Jaundice

Chest pain, shortness of breath, and a cough may indicate a serious reaction that should be addressed immediately.[1]

Keytruda for Mesothelioma

Right now, indications for Keytruda do not include most mesothelioma patients, but research is underway to determine if it could be an effective and safe treatment for this cancer.

A study published in The Lancet Oncology showed promising results. This study shows that while other chemotherapy drugs fail mesothelioma patients, immune checkpoint drugs may be a better alternative.

The clinical trial is called KEYNOTE-028 and involved thirteen research teams in six different countries. The trial included twenty-five patients with pleural mesothelioma who had already received at least one chemotherapy treatment before the trial.

Patients received a larger than normal dose of pembrolizumab every two weeks. As a result, 20% of the patients saw reductions in tumor size, and an additional 52% had stable disease. Patients who responded had an average of twelve months of response.[3]

In 2020, the FDA approved Keytruda for certain mesothelioma patients. The approval is contingent on genetic factors. This includes patients with solid tumors with a high tumor mutational burden. Mesothelioma is one of the most common cancers with this designation.[4]

A large clinical trial using Keytruda in mesothelioma patients published results in 2020. Researchers described the duration of response of the treatment as impressive. Patients in the trial received Keytruda as a second-line treatment after others elicited no response or stalled.[5]

Keytruda for Asbestos Lung Cancer

Pembrolizumab is promising for mesothelioma patients; however, the drug is already approved for non-small cell lung cancer (NSCLC), another cancer that can be triggered by asbestos exposure. Approval for treating this kind of cancer came after clinical trial results showed it to be safe and effective. More recent studies suggest it may be more effective than standard chemotherapy drugs like cisplatin and carboplatin.

KEYNOTE-024 was a clinical trial of pembrolizumab in non-small cell lung cancer patients whose tumors express PD-L1 at 50% or higher. Data showed pembrolizumab has several advantages over traditional chemotherapy.

Patients given this drug experienced better overall survival rates, fewer less severe side effects, and improved quality of life. While some side effects were worse with pembrolizumab, overall adverse effects were lower and less severe. The benefits of pembrolizumab were seen in its use as a first-line treatment.

This trial means patients with lung cancer may be prescribed pembrolizumab instead of cisplatin or carboplatin, avoiding chemotherapy side effects and possibly achieving better results.[6]

The promise of immunotherapy drugs for cancer treatment is overwhelmingly positive. Keytruda is paving the way to a new strategy for better treatment of mesothelioma. There are now more than ninety ongoing clinical trials using Keytruda to treat various types of cancers.

Approval for Keytruda Expands, Hope for Mesothelioma Patients

In June of 2019, the FDA announced a new indication for Keytruda. It is now approved for the first-line treatment of metastatic, unresectable, or recurrent head and neck squamous cell carcinoma (HNSCC).

The FDA has approved the immunotherapy drug as a combination treatment with chemotherapy and as a stand-alone treatment for HNSCC patients with PD-L1 expression on the tumor cells.

This is important news, not just for the HNSCC patients who may benefit from Keytruda but also for mesothelioma patients. HNSCC is a rare cancer that is difficult to treat, just like mesothelioma. The approval for pembrolizumab is an important step in giving mesothelioma patients more hope of improved survival.

It is also a step in the direction of getting drugs like this approved for other rare cancers. The approval came after the clinical trial KEYNOTE-048 showed the drug could significantly prolong patient survival.

Two new mesothelioma trials are expected to start soon. If you are struggling with mesothelioma, pembrolizumab is not currently approved for treatment; however, you may be able to participate in a clinical trial. Talk to your doctor about getting involved if you qualify for this revolutionary treatment for this difficult type of cancer.

Get Your FREE Mesothelioma Packet

Page Medically Reviewed and Edited by Kyle J. Becker, PharmD, MBA, BCOP

Kyle J. Becker

Kyle J. Becker, PharmD is certified by the Board of Pharmacy Specialties in Oncology Pharmacy. Dr. Becker earned his pharmacy degree from Shenandoah University and he currently serves as an oncology pharmacist at Parkview Cancer Institute.

Connect with Oncology Pharmacist Kyle J. Becker
References
  1. U.S. Food and Drug Administration. (2014). Keytruda.
    Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s004s006lbl.pdf
  2. U.S. Food and Drug Administration. (2017, May 23). FDA Approves First Cancer Treatment for Any Solid Tumor with a Specific Genetic Feature.
    Retrieved from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm560167.htm
  3. Alley, E.W., Lopez, J., Santoro, A., Morosky, R.N., Saraf, S., Piperdi, B., and van Brummelen, E. (2017, March 10). Clinical Safety and Activity of Pembrolizumab in Patients with Malignant Pleural Mesothelioma (KEYNOTE-028): Preliminary Results from a Non-Randomised, Open-Lable, Phase 1b Trial. The Lancet. 18(5), P623-30.
    Retrieved from: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30169-9/fulltext
  4. Astor, L. (2020, June 16). FDA Approves Pembrolizumab for TMB-High Solid Tumors. Targeted Oncology.
    Retrieved from: https://www.targetedonc.com/view/fda-approves-pembrolizumab-for-tmb-high-solid-tumors
  5. Doyle, C. (2020, November 25). Use of Pembrolizumab in Advanced Pleural Mesothelioma: Results From KEYNOTE-158. The ASCO Post.
    Retrieved from: https://ascopost.com/issues/november-25-2020/use-of-pembrolizumab-in-advanced-pleural-mesothelioma-results-from-keynote-158/
  6. Reck, M., Rodriquez-Abreu, D., Robinson, A.G., Hui, R., Csoszi, T., Fulop, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., HOtta, K., Leiby, M.A., Lubiniecki, G.M., Shentu, Y., Rangwala R., and Brahmer, J.R. (2016, November 10). Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N. Engl. J. Med. 375, 1823-33.
    Retrieved from: https://www.nejm.org/doi/10.1056/NEJMoa1606774
View All References

Site Navigation

Home
Malignant Mesothelioma
How to Survive Mesothelioma
100 Questions & Answers about Mesothelioma (Free Book)
Surviving Mesothelioma - Beating the Odds (Free Book)
FREE Mesothelioma Packet
Symptoms
Shortness of Breath
Cough
Night Sweats and Fever
Weight Loss
Pain
Difficulty Swallowing
Fatigue and Muscle Weakness
Gastrointestinal Complications
Diagnosis
Pathology
Staging
Stage 1
Stage 2
Stage 3
Stage 4
Metastasis and Progression
Brain Metastasis
Biopsy
miRview Test
Imaging
Fine Needle Aspiration Biopsy in Mesothelioma
Biomarkers and Blood Tests
Calretinin
Prognosis
Remission
Recurrence
Death Rate
Life Expectancy
Search for a Mesothelioma Cure
Types
Pleural
Peritoneal
Epithelioid
Sarcomatoid
Biphasic
Pericardial
Testicular
Cell Types
Rare Subtypes of Mesothelioma
Deciduoid
Desmoplastic
Heterologous
Lymphohistiocytoid
Well-Differentiated Papillary
Tubulopapillary
Small Cell
Benign
Adenomatoid
Cystic
Unresectable
Localized
Idiopathic
Omental
Causes
Risk Factors
Latest Research
Genetic Components
Incidence
Latency Period
Mesothelioma Tumor
Health Insurance Coverage
Related Conditions
Immunodeficiency Disorders
Cholangiocarcinoma
Atelectasis
Pleural Plaques
Pleural Thickening
Pleural Effusion
Peritoneal Effusion (Ascites)
Mesothelial Hyperplasia and Proliferation
Pleuritis and Pleurisy
COPD
Anemia
Breast Cancer
Prevention
Complications
Misdiagnosis
Mesothelioma Commercial
Talcum Baby Powder
Lawyer
Lawsuits
Class Action Lawsuits
Settlements
Simian Virus 40
Differences From Other Cancers
Lung Cancer
Women
Children and Young Adults
Unknown Asbestos Exposure
Mesothelioma Without Asbestos
Cause of Death
Facts 
History
Awareness
Government and Research
National Mesothelioma Virtual Bank
Support
What to Expect
Living with Mesothelioma
Help a Loved One
Wrong and Right Things to Say
Caregivers
Financial Tips
Faith
Nutrition and Lifestyle
Intimacy
Mesothelioma and Fertility in Men
Fertility in Women with Mesothelioma
Emotional Health
COVID-19
Assisted Living
Hospice Care
Dying from Mesothelioma
Mourning
Coping Guide for Children
End-of-Life Decisions
Mesothelioma Awareness Day
Compensation for Victims
Lawyer
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington D.C.
Washington
West Virginia
Wisconsin
Wyoming
Lawsuit
Settlements
Statute of Limitations
Treatment
Surgery
Side Effects
Pneumonectomy
Extrapleural Pneumonectomy
Lobectomy
Pleurectomy/Decortication
Post Op Care
Pleurectomy/Decortication vs. Extrapleural Pneumonectomy
Peritonectomy/Cytoreductive Surgery
Thoracotomy
Thoracoscopy
Pericardiectomy
Wedge Resection
Pleurodesis
Pericardiocentesis
Prosthetics
Paracentesis
Thoracentesis
Chemotherapy
Side Effects
Heated Intraperitoneal
Radiation Therapy
Side Effects
Intensity-Modulated
Brachytherapy
Proton Therapy
Image-Guided
External Beam
Three-Dimensional
Multimodal Therapy
New Treatments
SMART Protocol
Gene Therapy
Suicide Gene Therapy
Tumor-Based p53 Therapy
Cryotherapy for Mesothelioma
Tumor Treating Fields
MicroRNA
Palliative Treatment
Osteopathic
Doctors
Treatment Centers
Treatment & Doctors Near You
Mesothelioma Experts
Medications
Alimta (pemetrexed)
Adriamycin (doxorubicin)
Avastin (bevacizumab)
Cytoxan (cyclophosphamide)
Gemzar (gemcitabine)
Keytruda (Pembrolizumab)
Mitomycin
Navelbine (vinorelbine)
Opdivo (nivolumab) and Yervoy (ipilimumab)
Paraplatin (carboplatin)
Platinol (cisplatin)
Rheumatrex (methotrexate)
Sutent (sunitinib)
Taxol (paclitaxel)
Medical Marijuana
Care Providers
Clinical Trials
Anetumab Ravtansine
Atezolizumab
Chimeric Antigen Receptor (CAR) T-Cell
Durvalumab
Immunotoxin
Interferon Alfa-2b
Onconase (Ranpirnase)
VISTA Protein
Costs
Immunotherapy
Nanotechnology
Hyperbaric Oxygen Therapy
Home Medical Equipment
HMGB1 Secretion
Photodynamic Therapy
Targeted Therapies
Apoptosis
Stem Cells
Lung Transplantation
Body-Based Therapies
Alternative Therapies
Paul Kraus’s Method
Doctors and Treatment in Canada
Asbestos Trusts
Veterans
VA Claims for Mesothelioma
Vietnam Veterans
Military Branches and Asbestos
Navy Veterans
Navy Ships
Aircraft Carriers
Battleships
Destroyers
Asbestos on Navy Cruisers
Submarines
Amphibious Ships
Minesweepers
Auxiliary Ships
Marine Corps Veterans
Army Veterans
Air Force Veterans
U.S. Coast Guard
Asbestos
Occupational Exposure
Construction Workers
Shipyard Workers
Ship Repair
Steel Mill Workers
Industrial Workers
Boiler Workers
Power Plant Workers
Firefighters
Automotive Workers
Roofers
Oil Refineries
Mining
Transportation Industry
Machine Operators
Farmers and Agricultural Workers
Migrant Workers
Electrical Wiring
Labor Unions
Prisons
Chimneys, Furnaces, and Wood Stoves
Fiberglass Connection to Mesothelioma
Home Remodeling
School Buildings, Teachers
For Tech Students
Cancer
Lung Cancer
Pleural Based Cancers
Ovarian Cancer
Ovarian Cancer Lawsuits
Companies That Used Asbestos
Awareness and Education
Types of Asbestos & Mesothelioma Risk
Asbestosis
Interstitial Lung Disease
Smoking
Asbestos Ingestion
Exposure in a Natural Disaster
Ban Asbestos
Libby, Montana
Recycling Asbestos
Asbestos Detection
Legal Information by State
Canada
Mexico
United Kingdom
Australia
  • Malignant Mesothelioma
    • Treatment
    • Asbestos Trusts
  • Compensation
    • Veteran Assistance
    • Surviving Mesothelioma
  • FREE Mesothelioma Packet
    • Mesothelioma News
    • About Us / Contact
  • Privacy Policy
    • Disclaimer
    • Editorial Guidelines and Standards
This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.
The information provided by Mesothelioma.net is not a substitute for professional medical advice, diagnosis or treatment.

Mesothelioma.net

5430 LBJ Freeway Suite 1200
Dallas, Texas 75240

Serving mesothelioma victims nationwide

1-800-692-8608

  • facebook
  • twitter
© 2022 Mesothelioma.net